izalontamab
An immunoglobulin G (IgG) bispecific antibody targeting both the epidermal growth factor receptor (EGFR; HER1; ErbB1) and the epidermal growth factor receptor 3 (HER3; ErbB3), with potential antineoplastic activity. Upon administration, izalontamab simultaneously targets and binds to EGFR and HER3 expressed on cancer cells, thereby preventing receptor phosphorylation. This prevents the activation of both EGFR- and HER3-mediated signaling pathways and results in the inhibition of tumor cell proliferation. EGFR and HER3, both upregulated and/or mutated in a variety of tumor cell types, play key roles in tumor cell proliferation.
| Synonym: | anti-EGFR/anti-HER3 bi-specific monoclonal antibody SI-B001 anti-EGFR/HER3 bispecific antibody SI-B001 EGFR/HER3 bispecific antibody SI-B001 HER3 × EGFR SI-B001 HER3 x EGFR SI-B001 |
|---|---|
| Code name: | SI B001 SI-B001 SIB001 |